Muhammad W Saif

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. doi request reprint First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, 800 Washington Street, Boston, MA, 02111, USA
    Cancer Chemother Pharmacol 73:373-80. 2014
  2. doi request reprint Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 15:38-41. 2014
  3. doi request reprint A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach
    Muhammad Wasif Saif
    Division of Hematology Oncology and Experimental Therapeutics, Tufts Medical Center, Boston, MA Electronic address
    Mayo Clin Proc 89:131-6. 2014
  4. doi request reprint Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer
    Sun Young Oh
    Department of Hematology Oncology and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 14:676-9. 2013
  5. doi request reprint Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different
    Muhammad Wasif Saif
    Experimental Therapeutics Program, Tufts University School of Medicine, 800 Washington Street, Suite 7S 7099, Boston, MA 02111, USA 1 617 636 8077 1 617 636 7060
    Expert Opin Biol Ther 13:1489-93. 2013
  6. doi request reprint A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 14:498-501. 2013
  7. ncbi request reprint Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production: a case report and review of literature
    Forum B Patel
    Department of Medicine and Cancer Center, Tufts Medical Center, 800 Washington Street Box 245, Boston, MA 02111, U S A
    Anticancer Res 33:4001-5. 2013
  8. doi request reprint Utilizing endoscopic ultrasound-guided fine needle aspiration in identifying molecular targets for pancreatic cancer
    Onyekachi Henry Ogbonna
    Tufts University School of Medicine Boston, MA 02111, USA
    JOP 14:316-7. 2013
  9. doi request reprint Tumor markers in pancreatic cancer: 2013
    Urvi Ajay Shah
    Tufts Medical Center Boston, MA 02111, USA
    JOP 14:318-21. 2013
  10. doi request reprint First line therapy for metastatic pancreatic cancer
    Jamie Jarboe
    Tufts Cancer Center Boston, MA, USA
    JOP 14:340-3. 2013

Collaborators

  • Kostas N Syrigos
  • Simon Khagi
  • C Erlichman
  • Suzanne Russo
  • Alexios S Strimpakos
  • Jamie Jarboe
  • Urvi Ajay Shah
  • Forum B Patel
  • Muzzamal Habib
  • Najla Hatem El-Jurdi
  • Anastasios Dimou
  • Evangelos G Sarris
  • Vasilis Stefanos Ramfidis
  • Onyekachi Henry Ogbonna
  • Keith Leung
  • Sun Young Oh
  • Vassilis S Ramfidis
  • Froso Konstantinou
  • Wesam B Ahmed
  • Vassilios S Ramfidis
  • Meropi Panagiotarakou
  • Krishna S Gunturu
  • Dow Chung Chi
  • Vorawan Ummaritchot
  • Ronald M Lechan
  • Kevin P Daly
  • Nawal Wasif
  • Gladys Rodriguez
  • Marie Carmel Garcon
  • Ithamar Turenne
  • Sarah Zelonis
  • David E Wazer
  • Anumeha Gupta
  • John Ng
  • Frances Brogan
  • Lawrence Schwartz

Detail Information

Publications36

  1. doi request reprint First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, 800 Washington Street, Boston, MA, 02111, USA
    Cancer Chemother Pharmacol 73:373-80. 2014
    ..We conducted this phase II study to explore the efficacy of capecitabine and PHY906 in patients with advanced pancreatic cancer who were previously treated with gemcitabine-based regimens...
  2. doi request reprint Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 15:38-41. 2014
    ..The combination of etoposide and cisplatin is considered as the first-line treatment, but no recommendations exist for further treatment after progression...
  3. doi request reprint A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach
    Muhammad Wasif Saif
    Division of Hematology Oncology and Experimental Therapeutics, Tufts Medical Center, Boston, MA Electronic address
    Mayo Clin Proc 89:131-6. 2014
    ..This case suggests that Y186C may have contributed to 5-FU toxicity in this patient and supports the use of Y186C as a predictive marker for 5-FU toxic effects in individuals of African ancestry. ..
  4. doi request reprint Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer
    Sun Young Oh
    Department of Hematology Oncology and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 14:676-9. 2013
    ..Neurotoxicity is the dose limiting toxicity and ototoxicity is very rare, less than 1% of patients...
  5. doi request reprint Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different
    Muhammad Wasif Saif
    Experimental Therapeutics Program, Tufts University School of Medicine, 800 Washington Street, Suite 7S 7099, Boston, MA 02111, USA 1 617 636 8077 1 617 636 7060
    Expert Opin Biol Ther 13:1489-93. 2013
    ..The author comments on this issue and emphasizes the need for additional research into antiangiogenic biomarkers to identify patients who are likely to respond to one drug more than another. ..
  6. doi request reprint A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine Boston, MA, USA
    JOP 14:498-501. 2013
    ..Pancreatic neuroendocrine tumors (pNETs) are notoriously resistant to currently available chemotherapy agents. Preclinical data has suggested synergy between temozolomide and capecitabine...
  7. ncbi request reprint Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production: a case report and review of literature
    Forum B Patel
    Department of Medicine and Cancer Center, Tufts Medical Center, 800 Washington Street Box 245, Boston, MA 02111, U S A
    Anticancer Res 33:4001-5. 2013
    ..Although resection of the pancreatic mass was performed, the patient presented again with metastatic disease to the liver. ..
  8. doi request reprint Utilizing endoscopic ultrasound-guided fine needle aspiration in identifying molecular targets for pancreatic cancer
    Onyekachi Henry Ogbonna
    Tufts University School of Medicine Boston, MA 02111, USA
    JOP 14:316-7. 2013
    ..We summarize their findings and discuss the possibility of utilizing this model to obtain a better understanding of pancreatic cancer at each stage of its metamorphosis and target therapy at these different levels. ..
  9. doi request reprint Tumor markers in pancreatic cancer: 2013
    Urvi Ajay Shah
    Tufts Medical Center Boston, MA 02111, USA
    JOP 14:318-21. 2013
    ..We will discuss four abstracts presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which contribute to expanding the application of CA 19-9 measurement (Abstracts #4042, #4058, #e15082, #e15146). ..
  10. doi request reprint First line therapy for metastatic pancreatic cancer
    Jamie Jarboe
    Tufts Cancer Center Boston, MA, USA
    JOP 14:340-3. 2013
    ..We will discuss the results of the MPACT trial presented at the 2013 ASCO Annual Meeting (Abstracts #4005, #4058, and #4059) and compare to the 2011 FOLFIRINOX data. ..
  11. doi request reprint New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma
    Vasilis Stefanos Ramfidis
    University of Pittsburgh Cancer Institute Pittsburgh, PA, USA
    JOP 14:344-6. 2013
    ....
  12. doi request reprint Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
    Alexios S Strimpakos
    Division of Oncology, Second Department of Internal Medicine, Attikon University Hospital, Athens, Greece
    JOP 14:354-8. 2013
    ..The aforementioned early phase studies open new therapeutic approaches which deserve further testing in advanced pancreatic cancer. ..
  13. doi request reprint Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications
    Alexios S Strimpakos
    Division of Oncology, Second Department of Internal Medicine, Attikon University Hospital, Greece
    JOP 14:359-62. 2013
    ..Of course, there is a long way to go before implementation of these genomic findings, with the exception of hENT1 which seems to be close for clinical use. ..
  14. doi request reprint Diabetes and pancreatic cancer
    Najla Hatem El-Jurdi
    Tufts University School of Medicine Boston, MA 02111, USA
    JOP 14:363-6. 2013
    ....
  15. doi request reprint Update on novel therapies for pancreatic neuroendocrine tumors: 2013
    Anastasios Dimou
    Department of Medicine, Albert Einstein Medical Center Philadelphia, PA, USA
    JOP 14:377-80. 2013
    ..Last but not least, we discuss the updated data from a phase II study that used the combination of temsirolimus with bevacizumab in patients with advanced pNETs (Abstract #4032). ..
  16. ncbi request reprint Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    In Vivo 27:531-4. 2013
    ..The incidence of cardiotoxicity associated with 5-FU ranges from 1.5% to 18%; 48% as anginal symptoms and 2% as cardiogenic shock. Cardiotoxicity is unpredictable and no alternative chemotherapeutics have been defined so far...
  17. ncbi request reprint Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study
    Muhammad Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Anticancer Res 33:2743-6. 2013
    ..To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer...
  18. ncbi request reprint Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Muhammad Wasif Saif
    Division of Hematology Oncology, Department of Medicine, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Anticancer Res 33:2377-80. 2013
    ..The author reviews the data on anti-VEGF therapy in metastatic colorectal cancer...
  19. ncbi request reprint Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions
    Muhammad Wasif Saif
    Tufts University School of Medicine, Division of Hematology Oncology, Department of Medicine, Director, GI Oncology Program 800 Washington Street, Box 245, Boston, MA 02111, USA
    Anticancer Res 33:2175-7. 2013
    ..We share our experience using concurrent capecitabine or infusional 5-fluorouracil with radiation for patients with resected and locally advanced PNET...
  20. doi request reprint Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors
    M W Saif
    Hematology Oncology, Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Cancer Chemother Pharmacol 71:1345-55. 2013
    ..We have undertaken a Phase 1 trial of CNF1010, an oil-in-water nanoemulsion of 17-AAG...
  21. ncbi request reprint Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD
    Muhammad Wasif Saif
    Tufts Medical Center, Tufts University School of Medicine, Division of Hematology Oncology, Department of Medicine, Director, GI Oncology Program, 800 Washington Street, Box 245, Boston, MA 02111, USA
    Cancer Genomics Proteomics 10:89-92. 2013
    ..We present the analysis of DPYD genotyping in untreated Caucasian patients (control group) and Caucasian patients with 5-FU/CAP-related grade 3/4 toxicities (toxicity group) who underwent a capecitabine TheraGuide 5-FU testing...
  22. ncbi request reprint Adenocarcinoma ex goblet cell carcinoid in a renal transplant patient: a case report and review of the literature
    M Wasif Saif
    GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Anticancer Res 33:1753-6. 2013
    ..We report on a case of a 45-year-old woman, post-renal transplant who presented with ovarian metastases from this tumor. This appears to be the first report of an adenocarcinoma ex goblet cell carcinoid in a renal transplant recipient...
  23. ncbi request reprint Small cell carcinoma of the colon arising in a carcinoid tumor
    M Wasif Saif
    Section of GI Cancers and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA
    Anticancer Res 33:1713-5. 2013
    ..Although small cell carcinomas of the colon have frequently been found in association with colonic adenomas, this appears to be the first report of a low-grade carcinoid tumor in combination with a small cell carcinoma...
  24. doi request reprint Advancements in the management of pancreatic cancer: 2013
    Muhammad Wasif Saif
    Tufts Medical Center Boston, MA, USA
    JOP 14:112-8. 2013
    ..At the end of one year, 35% of those getting nab-paclitaxel were alive, compared with 22% of those getting only gemcitabine. After two years, the figures were 9% for those getting nab-paclitaxel and 4% for those who received gemcitabine...
  25. doi request reprint Thromboembolism and anticoagulation in pancreatic cancer
    Muzzamal Habib
    St Elizabeth s Medical Center, Boston, MA, USA
    JOP 14:135-7. 2013
    ..Additionally the authors review the risk of thrombosis associated with the chemotherapy and erythropoiesis stimulating agents and its prognostic implications and possible managements...
  26. doi request reprint Intraductal papillary mucinous neoplasms of the pancreas (IPMNs): epidemiology, diagnosis and future aspects
    Froso Konstantinou
    Oncology Unit, Third Department of Medicine, Athens School of Medicine, Sotiria General Hospital, Athens, Greece
    JOP 14:141-4. 2013
    ..Herein, the authors summarize the data presented at the 2013 ASCO Gastrointestinal Cancers Symposium regarding incidence and clinicopathological characteristics of IPMN (Abstracts #324, #187 and #179)...
  27. doi request reprint Pancreatic cancer: updates on translational research and future applications
    Evangelos G Sarris
    Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece
    JOP 14:145-8. 2013
    ..Lastly, in Abstract #164, the diagnostic utility of YKL-40 and IL-6 in pancreatic cancer patients is investigated...
  28. doi request reprint BRCA-associated pancreatic cancer: the evolving management
    Keith Leung
    Division of Hematology Oncology, Department of Medicine and Cancer Center, Tufts Medical Center, Boston, MA 02111, USA
    JOP 14:149-51. 2013
    ..We will review these abstracts and our current knowledge of the treatment for patients with BRCA-associated pancreatic cancer. In this group of patients, these new results continue to shape our understanding of this disease...
  29. doi request reprint Ampullary and periampullary adenocarcinoma: new challenges in management of recurrence
    Vassilis S Ramfidis
    Oncology Unit, 251 General Hospital of Airforce, Athens, Greece
    JOP 14:158-60. 2013
    ....
  30. ncbi request reprint Gemcitabine-induced pulmonary toxicity
    Dow Chung Chi
    Tufts Medical Center, Boston, MA 02111, USA
    Anticancer Res 32:4147-9. 2012
    ..Mild to moderate emphysema was also seen, but no pulmonary emboli were detected. Myocardial infraction was ruled-out by normal electrocardiogram and normal cardiac biomarkers...
  31. doi request reprint Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care
    Meropi Panagiotarakou
    Oncology Unit, Sotiria General Hospital, University of Athens, Athens, Greece
    JOP 13:342-4. 2012
    ..All of these abstracts explore innovative ways to control symptoms in cancer patients. We are hopeful that these methods are able to be used in symptomatic pancreatic cancer patients...
  32. doi request reprint New tools and novel approaches in treating locally advanced pancreatic adenocarcinoma
    Wesam B Ahmed
    Division of Hematology Oncology, Department of Radiation Oncology, Tufts Medical Center, Boston, MA 02111, USA
    JOP 13:354-7. 2012
    ..The phase II results showed a median overall survival of 15.9 months, suggesting that SBRT may be an emerging tool in the multi-modality treatment of locally advanced pancreatic cancer...
  33. doi request reprint Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
    Vassilios S Ramfidis
    Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece
    JOP 13:358-60. 2012
    ..Finally, the efficacy and toxicity of lapatinib combined with either FOLFOX (Abstract #e14533) or capecitabine (Abstract #e14569) were examined in the second line setting of pancreatic cancer...
  34. doi request reprint Highlights on the first line treatment of metastatic pancreatic cancer
    Krishna S Gunturu
    Department of Medicine and Cancer Center, Tufts Medical Center, Boston, MA 02111, USA
    JOP 13:361-7. 2012
    ..The 2012 American Society of Oncology (ASCO) Annual Meeting offered new insights into metastatic pancreatic cancer and we discuss Abstracts #4018, #4019, #4022, #4042, #4043, #4048, #4050 and comment on them in this paper...
  35. doi request reprint Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma
    Alexios S Strimpakos
    Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece
    JOP 13:338-41. 2012
    ....
  36. doi request reprint Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer
    Alexios S Strimpakos
    Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece
    JOP 13:345-8. 2012
    ....